Literature DB >> 36203011

High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging.

Shanshan He1, Ruchir Bhatt1, Carl Brown1, Emily A Brown1, Derek L Buhr1, Kan Chantranuvatana1, Patrick Danaher1, Dwayne Dunaway1, Ryan G Garrison1, Gary Geiss1, Mark T Gregory1, Margaret L Hoang1, Rustem Khafizov1, Emily E Killingbeck1, Dae Kim1,2, Tae Kyung Kim1, Youngmi Kim1, Andrew Klock1, Mithra Korukonda1, Alecksandr Kutchma1, Zachary R Lewis1, Yan Liang1, Jeffrey S Nelson1, Giang T Ong1, Evan P Perillo1, Joseph C Phan1, Tien Phan-Everson1, Erin Piazza1, Tushar Rane1, Zachary Reitz1, Michael Rhodes1, Alyssa Rosenbloom1, David Ross1, Hiromi Sato1, Aster W Wardhani1, Corey A Williams-Wietzikoski1, Lidan Wu1, Joseph M Beechem3.   

Abstract

Resolving the spatial distribution of RNA and protein in tissues at subcellular resolution is a challenge in the field of spatial biology. We describe spatial molecular imaging, a system that measures RNAs and proteins in intact biological samples at subcellular resolution by performing multiple cycles of nucleic acid hybridization of fluorescent molecular barcodes. We demonstrate that spatial molecular imaging has high sensitivity (one or two copies per cell) and very low error rate (0.0092 false calls per cell) and background (~0.04 counts per cell). The imaging system generates three-dimensional, super-resolution localization of analytes at ~2 million cells per sample. Cell segmentation is morphology based using antibodies, compatible with formalin-fixed, paraffin-embedded samples. We measured multiomic data (980 RNAs and 108 proteins) at subcellular resolution in formalin-fixed, paraffin-embedded tissues (nonsmall cell lung and breast cancer) and identified >18 distinct cell types, ten unique tumor microenvironments and 100 pairwise ligand-receptor interactions. Data on >800,000 single cells and ~260 million transcripts can be accessed at http://nanostring.com/CosMx-dataset .
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Year:  2022        PMID: 36203011     DOI: 10.1038/s41587-022-01483-z

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   68.164


  56 in total

1.  PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Authors:  Hui Yu; Cory Batenchuk; Andrzej Badzio; Theresa A Boyle; Piotr Czapiewski; Daniel C Chan; Xian Lu; Dexiang Gao; Kim Ellison; Ashley A Kowalewski; Christopher J Rivard; Rafal Dziadziuszko; Caicun Zhou; Maen Hussein; Donald Richards; Sharon Wilks; Marc Monte; William Edenfield; Jerome Goldschmidt; Ray Page; Brian Ulrich; David Waterhouse; Sandra Close; Jacek Jassem; Kimary Kulig; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-14       Impact factor: 15.609

2.  Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets.

Authors:  Evan Z Macosko; Anindita Basu; Rahul Satija; James Nemesh; Karthik Shekhar; Melissa Goldman; Itay Tirosh; Allison R Bialas; Nolan Kamitaki; Emily M Martersteck; John J Trombetta; David A Weitz; Joshua R Sanes; Alex K Shalek; Aviv Regev; Steven A McCarroll
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

3.  Oncologists await historic first: a pan-tumor predictive marker, for immunotherapy.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2017-04-11       Impact factor: 54.908

4.  Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.

Authors:  David T Ting; Doron Lipson; Suchismita Paul; Brian W Brannigan; Sara Akhavanfard; Erik J Coffman; Gianmarco Contino; Vikram Deshpande; A John Iafrate; Stan Letovsky; Miguel N Rivera; Nabeel Bardeesy; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2011-01-13       Impact factor: 47.728

5.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

6.  PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.

Authors:  Fred R Hirsch; Abigail McElhinny; Dave Stanforth; James Ranger-Moore; Malinka Jansson; Karina Kulangara; William Richardson; Penny Towne; Debra Hanks; Bharathi Vennapusa; Amita Mistry; Rasika Kalamegham; Steve Averbuch; James Novotny; Eric Rubin; Kenneth Emancipator; Ian McCaffery; J Andrew Williams; Jill Walker; John Longshore; Ming Sound Tsao; Keith M Kerr
Journal:  J Thorac Oncol       Date:  2016-11-29       Impact factor: 15.609

Review 7.  Molecular Tests for the Choice of Cancer Therapy.

Authors:  Anna P Sokolenko; Evgeny N Imyanitov
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 8.  PD-L1 Expression in Lung Cancer.

Authors:  Hui Yu; Theresa A Boyle; Caicun Zhou; David L Rimm; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-04-23       Impact factor: 15.609

Review 9.  PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.

Authors:  Margarita Udall; Maria Rizzo; Juliet Kenny; Jim Doherty; SueAnn Dahm; Paul Robbins; Eric Faulkner
Journal:  Diagn Pathol       Date:  2018-02-09       Impact factor: 2.644

10.  Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Authors:  H Halse; A J Colebatch; P Petrone; M A Henderson; J K Mills; H Snow; J A Westwood; S Sandhu; J M Raleigh; A Behren; J Cebon; P K Darcy; M H Kershaw; G A McArthur; D E Gyorki; P J Neeson
Journal:  Sci Rep       Date:  2018-07-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.